May 23 Could Bring Approval for Vertex's Hep C Drug
Vertex Pharma Hepatitis C Drug Incivek Likely to be Approved by May 23: Analyst
By IB Times Staff Reporter | May 4, 2011
RBC Capital Markets expects Vertex Pharmaceuticals Inc.’s (NASDAQ: VRTX) Incivek (telaprevir) to treat hepatitis C is likely to be approved on or around May 23.
“Once approved, we believe near-term performance in Vertex shares will be tied to launch metrics and continued progress in its pipeline including its Cystic Fibrosis (CF) drugs. We continue to believe that Incivek will receive a clean, broad label, including a simple treatment algorithm and side-effect management program,” said Jason Kantor, an analyst at RBC Capital Markets.
Continue reading this entire article: